Step 1 topics → General Pharmacology → Adrenergic Antagonists (α and β)

Adrenergic Antagonists (α and β)

USMLE Step 1 trap: Confuses the order of adrenergic blockade in pheochromocytoma, giving β-blocker first. α-blockade must always precede β-blockade because β-blockade alone removes β2-mediated vasodilation, leaving α1-mediated vasoconstriction unopposed and causing hypertensive crisis.

Adrenergic antagonists block α and/or β receptors, and USMLE Step 1 will push you far beyond simple drug-receptor matching. The exam tests whether you understand selectivity, reversibility, the physiologic consequences of blockade, and how these drugs interact with disease states. Expect vignettes where the 'obvious' answer is a trap — like reaching for a β-blocker first in a pheochromocytoma patient, or assuming a cardioselective agent is fully safe in asthma.

The two biggest axes to know: selectivity (α1 vs. non-selective α, β1-selective vs. non-selective β, and mixed α/β blockers like carvedilol and labetalol) and reversibility (phenoxybenzamine is irreversible; phentolamine is competitive/reversible). Indications follow mechanistically from receptor distribution — α1 receptors are in both vascular smooth muscle and the prostate, which is why tamsulosin treats BPH and why α1-blockers also lower blood pressure. USMLE Step 1 often tests whether you can apply receptor physiology to predict a drug's clinical use or its failure mode.

What makes this topic tricky is the layered reasoning required. Students memorize drug classes but stumble when the question requires integrating receptor physiology with clinical consequences — like why giving a β-blocker before an α-blocker in pheochromocytoma causes crisis, or why non-selective β-blockers are doubly dangerous in diabetics. The misconceptions below reflect the most common failure modes; fixing your mental model on each one will carry you a long way on test day.

From real student decks
92%have cards covering this topic
70%have mature cards
2.0median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Β-blockade can be given first or simultaneously with α-blockade in pheochromocytoma prep.
Right: α-blockade must always precede β-blockade because β-blockade alone removes β2-mediated vasodilation, leaving α1-mediated vasoconstriction unopposed and causing hypertensive crisis.
In pheochromocytoma, tumor catecholamines cause both α1-mediated vasoconstriction and β2-mediated vasodilation simultaneously. If you block β receptors first, you eliminate the β2 vasodilatory counterbalance while α1-mediated constriction remains fully active — the result is a severe, potentially fatal hypertensive crisis. α-blockade must come first to blunt the vasoconstriction, after which β-blockade can be added safely to control reflex tachycardia.
Common mistake
Wrong: Β-blockers only mask tachycardia in hypoglycemia but do not affect glucose recovery.
Right: Non-selective β-blockers both mask tachycardia (a warning sign) and blunt glycogenolysis, prolonging hypoglycemia in diabetic patients.
Non-selective β-blockers cause two distinct problems in diabetic patients on insulin or sulfonylureas: they mask tachycardia (a key early warning of hypoglycemia) AND they block β2-mediated hepatic glycogenolysis, which is the primary mechanism for recovering blood glucose. This means the patient can't feel the warning AND can't recover as quickly — a dangerous combination. Cardioselective β1-blockers still mask tachycardia and are still used cautiously, but the blunted glycogenolysis is the mechanism that makes non-selective agents particularly problematic.
Common mistake
Wrong: Cardioselective β1-blockers are completely safe in asthma because they do not block β2 receptors.
Right: Cardioselective β1-blockers have relative, not absolute, β1 selectivity and can still precipitate bronchospasm in asthma, making them relatively contraindicated.
The 'cardio' in cardioselective refers to a preference for β1 receptors, not exclusive binding. At higher doses, or in patients with severe reactive airway disease, β1-selective agents like metoprolol and atenolol will still occupy β2 receptors in bronchial smooth muscle and can precipitate bronchospasm. The selectivity is relative and dose-dependent, so these drugs are relatively contraindicated in asthma — they may be used with great caution when absolutely necessary, but they are never considered fully safe.
Common mistake
Wrong: Α1-blockers are used only for hypertension.
Right: α1-blockers (e.g., tamsulosin, terazosin) are used for both hypertension and benign prostatic hyperplasia because α1 receptors mediate smooth muscle contraction in both vessels and the prostate.
α1 receptors are expressed on smooth muscle in two major locations relevant here: vascular walls (where they cause vasoconstriction) and the prostate/bladder neck (where they cause smooth muscle contraction that obstructs urine flow). Blocking α1 in vessels lowers blood pressure; blocking α1 in the prostate relaxes the outlet and relieves urinary obstruction from BPH. Tamsulosin is specifically favored for BPH because its selectivity for prostate α1A receptors produces less orthostatic hypotension than non-selective α1 blockers like terazosin.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the key α-blockers by selectivity (α1-selective: prazosin, doxazosin, tamsulosin; non-selective: phenoxybenzamine, phentolamine), reversibility (phenoxybenzamine is irreversible/covalent; phentolamine is reversible), and their clinical indications — including both hypertension and BPH for the α1-selective agents.
  2. Classify β-blockers by selectivity: β1-selective (metoprolol, atenolol, esmolol) vs. non-selective (propranolol, timolol), and identify mixed α/β antagonists (carvedilol, labetalol) — know when you'd choose one group over another based on the clinical scenario.
  3. Explain why α-blockade must be established before β-blockade when preparing a pheochromocytoma patient for surgery — tracing the physiologic logic from catecholamine excess through receptor pharmacology to the consequence of unopposed vasoconstriction.
  4. Identify the adverse effects and contraindications of β-blockers, including bradycardia, masking of hypoglycemia symptoms, impaired glucose recovery with non-selective agents, bronchospasm risk in asthma, and exacerbation of Prinzmetal angina.

Can you avoid these mistakes?

A 45-year-old man with a pheochromocytoma is being prepared for adrenalectomy. The intern starts him on propranolol first to control his heart rate. Two hours later his blood pressure is 220/130 mmHg. What went wrong physiologically, and what should the correct preoperative sequence have been?
A patient with Type 1 diabetes on insulin is started on propranolol after an MI. What are the two distinct mechanisms by which this drug is dangerous in the setting of hypoglycemia, and which one would be avoided by switching to metoprolol?
A vignette describes a 70-year-old man with BPH and hypertension who experiences dizziness upon standing after a new medication is started. The drug reduces both his urinary hesitancy and his blood pressure. What receptor does this drug block, and name one agent you would expect to cause less orthostatic hypotension while still targeting BPH?
You need to prescribe a β-blocker for rate control in a patient with a history of mild persistent asthma and new-onset atrial fibrillation. A colleague says 'just use metoprolol, it's β1-selective so it's safe.' How would you correct this reasoning, and how does selectivity actually work at high doses?

Related topics

Adrenergic Agonists (Direct) ADME and Bioavailability Volume of Distribution (Vd) Clearance and Half-Life First-Order vs Zero-Order Elimination

See how your Anki deck covers this topic.

Upload your deck for a free audit →